MoonLake Immunotherapeutics (MLTX): Cash & Equivalents
$334.52M
As of 2025-12-31
$477.90M
As of 2026-06-30
+103.8%
3-year compound annual growth
n/m
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $334.52M | +85.4% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $180.43M | -60.0% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $451.17M | n/m | 2025-02-26, Balance as of period end |
| 2022-12-31 | $39.51M | +391.4% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $8.04M | +501.7% | 2023-03-20, Balance as of period end |
| 2020-12-31 | $1.34M | n/a | 2022-02-17, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | 2025-12-31 | $334.52M | +85.4% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $84.22M | -34.2% |
| Bicara Therapeutics Inc. (BCAX) | 2025-12-31 | $96.69M | -80.3% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $42.91M | -39.9% |
| BGM Group Ltd. (BGM) | 2025-09-30 | $9.82M | 0.0% |
| Alumis Inc. (ALMS) | 2025-12-31 | $89.67M | -47.1% |
| Oric Pharmaceuticals, Inc. (ORIC) | 2025-12-31 | $45.67M | -23.1% |
| Nkarta, Inc. (NKTX) | 2025-12-31 | $39.63M | +42.2% |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | 2025-12-31 | $373.69M | n/m |
Compare MLTX, STOK, BCAX, ARQT side by side · Screen every company in Pharmaceutical Preparations ↗